Benign prostatic hyperplasia risk up with higher percentage total food weight from ultraprocessed food

Among middle-aged and older men, a higher percentage of total food weight from ultraprocessed food (UPF) is associated with a ...

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia ...
European Medical Journal

PSA Levels Drop Rapidly After Surgery for Benign Prostate Enlargement

PSA clearance after BPE surgery follows a rapid, predictable pattern. Learn how TURP and OSP impact PSA levels and clinical ...
Pharmabiz

HistoSonics treats first patients evaluating the Edison Histotripsy System to treat benign prostatic hyperplasia

HistoSonics treats first patients evaluating the Edison Histotripsy System to treat benign prostatic hyperplasia: Minneapolis Wednesday, April 1, 2026, 14:00 Hrs [IST] HistoSonics ...

Medicus Pharma submits optimized Phase 2 study design for Teverelix

Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to announce that the company has ...
Endovascular Today

WOLVERINE Feasibility Trial Begins for HistoSonics Edison Histotripsy System to Treat BPH

HistoSonics announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial of the ...

Exclusive: Medicus Pharma refines trial design to cut costs, accelerate development for enlarged prostate patients

Medicus Pharma Ltd. MDCX said Monday it has submitted an optimized Phase 2 study design to the U.S. Food and Drug ...

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target MarketPHILADELPHIA, April 06, 2026 (GLOBE ...
Nature

Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia

Botulinum toxin A (BTX-A) is produced by the Gram-positive, anaerobic bacillus Clostridium botulinum, and is regarded as the most potent neurotoxin known to man The effects of BTX-A include inhibition ...

Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System

World’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for ...
Medical Device and Diagnostic Industry (MD+DI)

HistoSonics's WOLVERINE Trial for Edison System Begins

HistoSonics reported the successful treatment of the first patients in WOLVERINE, a new trial evaluating the Edison ...